Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06760637 · ClinicalTrials.gov registry record · Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
A Phase 3 study of Breast Cancer, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,020
- Enrollment target
- 20
- Study locations
NCT06760637 is a Phase 3 study of Breast Cancer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 1,020 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT06760637, a Phase 3 study of Breast Cancer, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,020 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Conditions Studied
Interventions
- DRUG abemaciclib
- DRUG PF-07220060
- DRUG letrozole
- DRUG palbociclib
- DRUG ribociclib
Study Locations (20)
Arkansas
- CARTI Cancer Center Saline County - Bryant
- CARTI Cancer Center Conway - Conway
- Highlands Oncology - Fayetteville
- CARTI Cancer Center - Little Rock
- CARTI Cancer Center North Little Rock Urology - North Little Rock
- CARTI Cancer Center North Little Rock - North Little Rock
- CARTI Cancer Center Pine Bluff - Pine Bluff
- Highlands Oncology - Rogers
- Highlands Oncology Group - Springdale
Arizona
- Ironwood Cancer & Research Centers - Chandler
- Ironwood Cancer & Research Centers - Gilbert
- Ironwood Cancer & Research Centers - Glendale
- Ironwood Cancer & Research Centers - Goodyear
- Ironwood Cancer & Research Centers - Mesa
- Ironwood Cancer & Research Centers - Mesa
- Ironwood Cancer & Research Centers - Phoenix
- Ironwood Cancer & Research Centers - Scottsdale
Alabama
- The Kirklin Clinic of UAB Hospital - Birmingham
- The University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham Hospital - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2025-01-06 |
| Est. Completion | 2037-12-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06760637
The ClinicalTrials.gov registry entry for NCT06760637 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,020 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which abemaciclib is the first listed.
NCT06760637 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Arkansas, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06760637 about?
NCT06760637 is a clinical study titled "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease". The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * ...
What is the current status of trial NCT06760637?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,020 participants. The study started on 2025-01-06. Estimated completion is 2037-12-29.
What conditions does trial NCT06760637 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT06760637?
The interventions under investigation include: abemaciclib (DRUG), PF-07220060 (DRUG), letrozole (DRUG), palbociclib (DRUG), ribociclib (DRUG).
Who is sponsoring clinical trial NCT06760637?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06760637 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.